DavidChenMDFACS(He/Him)

Urology • Rockledge, PA

Minimally Invasive Surgery, Surgical Oncology, Trauma & Reconstructive Surgery

Professor of Urologic Oncology; Associate Director, Urologic Oncology Fellowship Program

Join to view full profile

Dr. Chen is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chen's full profile

Already have an account?

Office
50 Huntingdon Pike
2nd Floor
Rockledge, PA 19046

Summary

David Chen, MD, is a Urologist based in Rockledge, PA, specializing in minimally invasive surgery, surgical oncology, and trauma and reconstructive surgery. He completed his medical education at Weill Cornell Medicine, followed by residencies in surgery and urology and a fellowship in urologic surgical oncology at New York Presbyterian Hospital. A Professor of Urologic Oncology at Fox Chase Cancer Center since 2004, Dr. Chen has research interests in genitourinary cancers, including renal neoplasms and prostate cancer. His recent publications include studies on bladder cancer and prostate cancer management. He has conducted clinical trials on innovative therapies for prostate and bladder cancer. Dr. Chen is recognized as a Fellow of the American College of Surgeons and has received certification for CMS Meaningful Use Stage 1.

Education & Training

New York Presbyterian Hospital (Columbia and Cornell Campus)Fellowship, Urologic Surgical Oncology, 2003 - 2004
New York Presbyterian Hospital (Cornell Campus)Residency, Urology, 1999 - 2003
New York Presbyterian Hospital (Cornell Campus)Residency, Surgery, 1997 - 1999
Weill Cornell MedicineClass of 1997
National Cancer InstituteHHMI-NIH Research Scholar, Urologic Oncology, 1994 - 1996

Certifications & Licensure

PA State Medical License 2004 - 2026
NJ State Medical License 2021 - 2025
NY State Medical License 1998 - 2004
American Board of Urology Urology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Fellow (FACS) American College of Surgeons

Clinical Trials

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
ACTIVE_NOT_RECRUITING
PHASE3
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma Start of enrollment: 2012 Nov 01
Terminated
Phase 3
Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery) Start of enrollment: 2013 Mar 18
Completed
Phase 2
A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection Start of enrollment: 2015 Oct 05
Terminated
Phase 3
Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus Start of enrollment: 2015 Sep 23
Terminated
Phase 2
Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients Start of enrollment: 2015 Dec 01
Completed
Phase 2
Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057) Start of enrollment: 2016 Feb 10
ACTIVE_NOT_RECRUITING
PHASE2
Study of NanoKnife for Ablation of Prostate Cancer in Intermediate Risk Patients Start of enrollment: 2021 May 13
Active, not recruiting
Not Applicable
A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer Start of enrollment: 2020 Dec 01
Active, not recruiting
Phase 2
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder Start of enrollment: 2017 Nov 21
RECRUITING
PHASE1, PHASE2
Dose Dense MVAC for Muscle Invasive Bladder Cancer Start of enrollment: 2009 Dec 07
Completed
Phase 2
Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder Start of enrollment: 2016 Nov 11
Active, not recruiting
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).
Daniel M Geynisman, Philip H Abbosh, Eric Ross, Matthew R Zibelman, Pooja Ghatalia
Journal of Clinical Oncology. 2025-03-20
A Randomized, Controlled Trial Evaluating Perioperative Risk-stratification and Risk-based, Protocol-driven Management After Elective Major Cancer Surgery.
Nestor F Esnaola, Raju Chelluri, Jason Castellanos, Ariella Altman, David Y T Chen
Annals of Surgery. 2025-03-01
2 citations
Comparison of perioperative and subacute postoperative complications between LDR and HDR monotherapy brachytherapy for prostate cancer.
Peter L Lee, Karen Ruth, Douglas Y Lee, Mark A Hallman, David Y T Chen
Brachytherapy. 2024-07-26

Authored Content

Innovative Transperineal Biopsy TechniqueJanuary 2018

Committees

Member, SUO Fellowship Committee 2023 - Present

Professional Memberships

American Urological Association - AUA
Member
American College of Surgeons - ACS
Member

External Links

Web profilehttps://www.foxchase.org/david-chen
Fellowship programhttps://www.foxchase.org/research/education/clinical-training-programs/fellowships/urologic-oncology-fellowship
Googlehttps://goo.gl/fSBgrj